<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133886</url>
  </required_header>
  <id_info>
    <org_study_id>DEC-MDS</org_study_id>
    <nct_id>NCT01133886</nct_id>
  </id_info>
  <brief_title>Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure</brief_title>
  <acronym>DEC-MDS</acronym>
  <official_title>Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the response rate at 6 months in Myelodysplastic&#xD;
      Syndrome (MDS) patients, Chronic Myelomonocytic Leukaemia (CMML-2) patients, and Acute&#xD;
      Myeloid Leukaemia (AML) patients with up to 30% bone marrow blasts, treated with low-dose&#xD;
      decitabine who have previously failed therapy with 5-azacitidine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate in the efficacy-evaluable (EE) population</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to AML progression (for MDS and CMML-2 patients only) or death</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematological improvement</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion requirements</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytogenetic response</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related toxicity</measure>
    <time_frame>Up until one month after last IMP dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Patients will receive decitabine as a 20mg/m2 one hour intravenous infusion once daily on days 1 to 5 of a 4 week cycle.</description>
    <arm_group_label>Decitabine</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written signed informed consent.&#xD;
&#xD;
          2. â‰¥18 years of age.&#xD;
&#xD;
          3. Diagnosed MDS with 5% or more marrow blasts and IPSS risk intermediate 2 or high risk;&#xD;
             or chronic myelomonocytic leukemia (CMML-2); or AML with 20-30% bone marrow blasts.&#xD;
&#xD;
          4. Patients who have failed therapy with azacitidine.&#xD;
&#xD;
          5. Performance status 0-2 (ECOG scale).&#xD;
&#xD;
          6. Adequate hepatic (bilirubin &lt; 1.5 X ULN or AST&lt; 2.5 X ULN) and renal functions&#xD;
             (creatinine &lt;1.5 X ULN).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Nursing and pregnant females.&#xD;
&#xD;
          2. Females of childbearing potential and males not willing to practice an effective&#xD;
             method of contraception whilst receiving decitabine and for 2 months after the last&#xD;
             infusion.&#xD;
&#xD;
          3. Patients with previous malignancy or concurrent malignancy.&#xD;
&#xD;
          4. Uncontrolled intercurrent illness including, but not limited to, symptomatic&#xD;
             congestive heart failure and unstable angina pectoris.&#xD;
&#xD;
          5. Ongoing oral corticosteroids are not permitted. However, use of corticosteroids&#xD;
             (topical and inhaled) is permitted and prophylactic steroids are allowed for&#xD;
             transfusion reactions.&#xD;
&#xD;
          6. Patients who have received any investigational agent within the 30 days preceding the&#xD;
             first dose of study drug.&#xD;
&#xD;
          7. Patients who have received prior intensive combination chemotherapy or high-dose&#xD;
             cytarabine (&gt;/= 1g/m*2 per dose). (Prior biologic therapies, targeted therapies and&#xD;
             single agent chemotherapy are allowed).&#xD;
&#xD;
          8. Patients who have an active viral or bacterial infection. Note: No patient is allowed&#xD;
             to enter the study unless infections have been fully treated and the patient has&#xD;
             remained afebrile for 7 days without antibiotics.&#xD;
&#xD;
          9. Patients who have concurrent autoimmune hemolytic anemia or immune thrombocytopenia.&#xD;
&#xD;
         10. Patients who have previously been treated with decitabine.&#xD;
&#xD;
         11. Patients who have known positive serology for HIV.&#xD;
&#xD;
         12. Patients with a condition that may be unable to comply with the treatment and&#xD;
             monitoring requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghulam J Mufti, MB, DM, FRCP, FRCPath</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ghulam J Mufti, MB, DM, FRCP, FRCPath</last_name>
    <phone>+44 (0) 20 3299 9000</phone>
    <phone_ext>3238</phone_ext>
    <email>ghulam.mufti@kcl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghulam J Mufti, MB, DM, FRCP, FRCPath</last_name>
      <phone>+44 (0) 20 3299 9000</phone>
      <phone_ext>3238</phone_ext>
      <email>ghulam.mufti@kcl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>May 28, 2010</study_first_submitted>
  <study_first_submitted_qc>May 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2010</study_first_posted>
  <last_update_submitted>September 2, 2010</last_update_submitted>
  <last_update_submitted_qc>September 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Professor Ghulam Mufti</name_title>
    <organization>King's College London</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

